JP7313058B2 - 組織器官の繊維化を予防及び治療するための方法 - Google Patents

組織器官の繊維化を予防及び治療するための方法 Download PDF

Info

Publication number
JP7313058B2
JP7313058B2 JP2019531811A JP2019531811A JP7313058B2 JP 7313058 B2 JP7313058 B2 JP 7313058B2 JP 2019531811 A JP2019531811 A JP 2019531811A JP 2019531811 A JP2019531811 A JP 2019531811A JP 7313058 B2 JP7313058 B2 JP 7313058B2
Authority
JP
Japan
Prior art keywords
plasminogen
fibrosis
administered
mice
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019531811A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512288A (ja
JP2020512288A5 (https=
Inventor
季男 李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Talengen International Ltd
Original Assignee
Talengen International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talengen International Ltd filed Critical Talengen International Ltd
Publication of JP2020512288A publication Critical patent/JP2020512288A/ja
Publication of JP2020512288A5 publication Critical patent/JP2020512288A5/ja
Application granted granted Critical
Publication of JP7313058B2 publication Critical patent/JP7313058B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2019531811A 2016-12-15 2017-06-19 組織器官の繊維化を予防及び治療するための方法 Active JP7313058B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016110174 2016-12-15
CNPCT/CN2016/110174 2016-12-15
PCT/CN2017/089058 WO2018107698A1 (zh) 2016-12-15 2017-06-19 一种预防和治疗组织器官纤维化的方法

Publications (3)

Publication Number Publication Date
JP2020512288A JP2020512288A (ja) 2020-04-23
JP2020512288A5 JP2020512288A5 (https=) 2020-07-30
JP7313058B2 true JP7313058B2 (ja) 2023-07-24

Family

ID=62557850

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019531811A Active JP7313058B2 (ja) 2016-12-15 2017-06-19 組織器官の繊維化を予防及び治療するための方法
JP2019531808A Active JP7213553B2 (ja) 2016-12-15 2017-06-19 肺の繊維化を予防及び治療するための方法
JP2019531805A Active JP7213552B2 (ja) 2016-12-15 2017-06-19 肝の繊維化を予防及び治療するための方法
JP2019531806A Pending JP2020502132A (ja) 2016-12-15 2017-06-19 皮膚の繊維化を予防及び治療するための方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019531808A Active JP7213553B2 (ja) 2016-12-15 2017-06-19 肺の繊維化を予防及び治療するための方法
JP2019531805A Active JP7213552B2 (ja) 2016-12-15 2017-06-19 肝の繊維化を予防及び治療するための方法
JP2019531806A Pending JP2020502132A (ja) 2016-12-15 2017-06-19 皮膚の繊維化を予防及び治療するための方法

Country Status (7)

Country Link
US (4) US11154595B2 (https=)
EP (4) EP3556382A4 (https=)
JP (4) JP7313058B2 (https=)
CN (4) CN110191718A (https=)
CA (3) CA3046671C (https=)
TW (6) TWI657823B (https=)
WO (5) WO2018107694A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11154595B2 (en) 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis
CA3067890A1 (en) 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CA3167593A1 (en) * 2020-02-11 2021-08-19 Jinan Li Method and drug for treating viral pneumonia
TWI910217B (zh) * 2020-08-20 2026-01-01 大陸商深圳瑞健生命科學研究院有限公司 一種治療腫瘤的方法和藥物
CN114984032B (zh) * 2022-06-27 2023-07-07 四川大学 Dna四面体框架核酸-绿原酸复合物及其在制备治疗肝纤维化的药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502600A (ja) 2006-08-28 2010-01-28 オムニオ・ヒーラー・アクチボラゲット 感染症に対する候補薬
JP2016529255A (ja) 2013-08-13 2016-09-23 サノフイ プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4645668A (en) 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
GB8721951D0 (en) 1987-09-18 1987-10-28 Thrombosis Research Trust Organic compounds
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
WO1997041824A2 (en) 1996-05-03 1997-11-13 Abbott Laboratories Antiangiogenic peptides derived from plasminogen
EP1001985A1 (en) 1997-06-26 2000-05-24 Karolinska Innovations AB Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
AU5571799A (en) * 1998-08-20 2000-03-14 University Of Vermont And State Agricultural College, The Angiogenesis inhibitors and uses thereof
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
US20030054988A1 (en) * 2000-11-02 2003-03-20 Weidong-Richard Ji Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
MXPA00011713A (es) 2000-11-28 2002-05-31 Tgt Lab S A De C V Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
DE10390418D2 (de) * 2002-02-06 2005-01-13 N Zyme Biotec Gmbh Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
AU2003210137A1 (en) * 2002-02-06 2003-09-02 N-Zyme Biotec Gmbh Method for producing recombinant proteins in micro-organisms
EP1509236A4 (en) 2002-05-13 2008-07-30 Children S Hospital Los Angele TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS
BR0316583A (pt) 2002-12-10 2005-10-04 Wyeth Corp Derivados de ácido acético 3-alquil e 3-arilalquil 1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
US20050250694A1 (en) 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
JP2008510814A (ja) 2004-08-23 2008-04-10 ワイス Ｐａｉ−１阻害剤としてのピロロ−ナフチル酸
US20100080773A1 (en) 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
PL2220221T3 (pl) 2007-11-29 2015-07-31 Grifols Therapeutics Inc Rekombinacyjnie zmodyfikowana plazmina
WO2009111625A2 (en) * 2008-03-05 2009-09-11 Board Of Regents, The University Of Texas System Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis
WO2011004011A1 (en) 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
CN101628113B (zh) 2009-08-18 2012-01-04 南京农业大学 蚯蚓纤溶酶抗肝纤维化的应用
NZ600160A (en) 2009-11-07 2014-05-30 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011139974A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
JP6085568B2 (ja) 2011-01-05 2017-02-22 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
EP3593861B1 (en) 2012-03-09 2022-12-14 Vascular Biosciences Combination of car peptide and a vasodilator for treating pulmonary hypertension
KR101467109B1 (ko) 2013-07-10 2014-12-01 영남대학교 산학협력단 Ｂｉｘ02189 화합물을 유효성분으로 포함하는 폐섬유증 예방 또는 치료용 조성물
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
TW201734054A (zh) 2013-08-13 2017-10-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
WO2015026494A2 (en) 2013-08-20 2015-02-26 Trustees Of Dartmouth College Methods for treating tissue fibrosis
CA2939897A1 (en) 2014-02-21 2015-08-27 Astellas Pharma Inc. New anti-human pai-1 antibody
PY1577621A (es) 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
TWI624268B (zh) 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備藥劑上的用途及包括纖溶酶原之藥劑
CN106890320A (zh) 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种用于预防或治疗急性及慢性血栓的方法
WO2017101873A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗放射性和化学性损伤的方法
CA3008185C (en) 2015-12-18 2024-01-16 Talengen International Limited Method for prevention or treatment of acute and chronic thrombosis
CN106890324A (zh) 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
CN106890318A (zh) 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病性心脏病的新方法
WO2017101867A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
EP3556386A4 (en) 2016-12-15 2020-07-08 Talengen International Limited METHOD FOR PREVENTING AND TREATING MEDICINALLY INDUCED KIDNEY INJURY
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
WO2018107707A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种改善心脏病变的方法
WO2018107688A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗脂肪肝的方法
JP7175270B2 (ja) 2016-12-15 2022-11-18 タレンゲン インターナショナル リミテッド グルカゴン、インスリンを正常なバランスに戻らせる方法
US11154595B2 (en) 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis
CA3067890A1 (en) 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502600A (ja) 2006-08-28 2010-01-28 オムニオ・ヒーラー・アクチボラゲット 感染症に対する候補薬
JP2016529255A (ja) 2013-08-13 2016-09-23 サノフイ プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hemostasis，1988年，vol.18, suppl.1，p.165-175
血液と脈管，1981年，vol.12, no.3，p.493-501
選択的plasminogen activator inhibitor‐1(PAI‐1)阻害剤による肝線維化抑制効果，日本消化器病学会雑誌，2013年02月20日，Vol.110 臨時増刊号，Page.A421, P467

Also Published As

Publication number Publication date
WO2018107694A1 (zh) 2018-06-21
EP3556380A1 (en) 2019-10-23
TW202123955A (zh) 2021-07-01
US20190314466A1 (en) 2019-10-17
EP3556382A4 (en) 2020-12-09
CN110121358A (zh) 2019-08-13
TW201822795A (zh) 2018-07-01
US11154595B2 (en) 2021-10-26
US11071772B2 (en) 2021-07-27
WO2018107698A1 (zh) 2018-06-21
EP3556395A4 (en) 2020-07-22
US20190314467A1 (en) 2019-10-17
TW201822783A (zh) 2018-07-01
TW201822790A (zh) 2018-07-01
US11219669B2 (en) 2022-01-11
EP3556389A1 (en) 2019-10-23
EP3556380A4 (en) 2020-05-13
CA3046671C (en) 2023-08-08
CN110114080A (zh) 2019-08-09
TW201822796A (zh) 2018-07-01
JP7213553B2 (ja) 2023-01-27
JP2020502133A (ja) 2020-01-23
JP2020512288A (ja) 2020-04-23
TWI670075B (zh) 2019-09-01
TWI734798B (zh) 2021-08-01
TWI657823B (zh) 2019-05-01
CA3046669A1 (en) 2018-06-21
TWI752044B (zh) 2022-01-11
EP3556389A4 (en) 2020-07-15
EP3556395A1 (en) 2019-10-23
WO2018107693A1 (zh) 2018-06-21
WO2018107696A1 (zh) 2018-06-21
TW201822789A (zh) 2018-07-01
CA3046671A1 (en) 2018-06-21
JP2020502132A (ja) 2020-01-23
EP3556382A1 (en) 2019-10-23
CN110191718A (zh) 2019-08-30
JP7213552B2 (ja) 2023-01-27
US20190314468A1 (en) 2019-10-17
WO2018107697A1 (zh) 2018-06-21
US20190365872A1 (en) 2019-12-05
JP2020511413A (ja) 2020-04-16
CA3046666A1 (en) 2018-06-21
CN110139668A (zh) 2019-08-16
CA3047174A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
JP7313058B2 (ja) 組織器官の繊維化を予防及び治療するための方法
HK1257584A1 (zh) 预防和治疗系统性硬化症的药物及其用途
WO2018107695A1 (zh) 一种预防和治疗肾纤维化的方法
CN108210893A (zh) 预防和治疗肾纤维化的药物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230606

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230704

R150 Certificate of patent or registration of utility model

Ref document number: 7313058

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150